# Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)

> **NCT02662985** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 166 (actual)

## Conditions studied

- Psoriatic Arthritis

## Interventions

- **DRUG:** AIN457 (secukinumab)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02662985
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08-22
- **Primary completion:** 2020-11-10
- **Final completion:** 2020-11-10
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2021-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02662985

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02662985, "Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02662985. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*